Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20040098042 A1
Publication typeApplication
Application numberUS 10/453,709
Publication dateMay 20, 2004
Filing dateJun 3, 2003
Priority dateJun 3, 2002
Also published asCA2486919A1, CA2486919C, EP1509144A1, EP1509144A4, US20070198060, US20130253538, WO2003101312A1, WO2003101312B1
Publication number10453709, 453709, US 2004/0098042 A1, US 2004/098042 A1, US 20040098042 A1, US 20040098042A1, US 2004098042 A1, US 2004098042A1, US-A1-20040098042, US-A1-2004098042, US2004/0098042A1, US2004/098042A1, US20040098042 A1, US20040098042A1, US2004098042 A1, US2004098042A1
InventorsCarol Devellian, Robert Carr
Original AssigneeDevellian Carol A., Carr Robert M.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Device with biological tissue scaffold for percutaneous closure of an intracardiac defect and methods thereof
US 20040098042 A1
Abstract
The invention provides an intracardiac occluder, which has biological tissue scaffolds as occlusion shells, for the percutaneous transluminal treatment of an intracardiac defect. The intracardiac occluder includes a proximal support structure supporting the proximal occlusion shell and a distal support structure supporting the distal occlusion shell. In one embodiment, biological tissue derived from the tunica submucosa layer of the porcine small intestine forms the occlusion shells.
Images(9)
Previous page
Next page
Claims(17)
What is claimed is:
1. An intracardiac occluder for percutaneous transluminal treatment of an intracardiac defect, comprising:
a proximal support structure supporting a proximal occlusion shell; and
a distal support structure, coupled to the proximal support structure, supporting a distal occlusion shell,
wherein at least one of the occlusion shells comprises a biological tissue scaffold.
2. The occluder of claim 1, wherein the biological tissue scaffold comprises a purified bioengineered type 1 collagen.
3. The occluder of claim 2, wherein the purified bioengineered type 1 collagen is derived from a tunica submucosa layer of a porcine small intestine.
4. The occluder of claim 1, wherein at least one of the support structures comprises a corrosion resistant metal.
5. The occluder of claim 1, wherein at least one of the support structures comprises a bioresorbable polymer.
6. The occluder of claim 1, wherein at least one of the support structures comprises a biodegradable polymer.
7. The occluder of claim 1, wherein the proximal support structure comprises a plurality of outwardly extending proximal arms and the distal support structure comprises a plurality of outwardly extending distal arms.
8. A method for percutaneous transluminal treatment of an intracardiac defect in a patient, comprising:
providing an intracardiac occluder, comprising:
a proximal support structure supporting a proximal occlusion shell; and
a distal support structure, coupled to the proximal support structure, supporting a distal occlusion shell,
wherein at least one of the occlusion shells comprises a biological tissue scaffold;
positioning the intracardiac occluder proximate the intracardiac defect; and
engaging the intracardiac defect with the intracardiac occluder to substantially occlude the intracardiac defect.
9. The method of claim 8, wherein engaging the intracardiac defect comprises positioning the proximal occlusion shell and the distal occlusion shell on different sides of the intracardiac defect.
10. The method of claim 8, wherein the intracardiac defect is a patent foramen ovale.
11. The method of claim 8, wherein the intracardiac defect is an atrial septal defect.
12. The method of claim 8, wherein the intracardiac defect is a ventricular septal defect.
13. The method of claim 8, wherein the intracardiac defect is a left atrial appendage.
14. A method for making an intracardiac occluder for percutaneous transluminal treatment of an intracardiac defect, comprising:
providing an overall support structure comprising a proximal support structure and a distal support structure;
providing first and second biological tissue scaffolds;
coupling the first biological tissue scaffold to the proximal support structure; and
coupling the second biological tissue scaffold to the distal support structure.
15. The method of claim 14, wherein coupling the biological tissue scaffolds comprises sewing the biological tissue scaffolds to the support structures.
16. The method of claim 14, wherein coupling the biological tissue scaffolds comprises laminating the biological tissue scaffolds to the support structures.
17. The method of claim 14, wherein coupling the biological tissue scaffolds comprises gluing the biological tissue scaffolds to the support structures.
Description
CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application incorporates by reference, and claims priority to and the benefit of, U.S. provisional application serial No. 60/385,274, which was filed Jun. 3, 2002.

TECHNICAL FIELD

[0002] The invention generally relates to devices and related methods for treating intracardiac defects. More particularly, the invention provides an intracardiac occluder with a biological tissue scaffold, and related methods, for the percutaneous closure of intracardiac defects.

BACKGROUND

[0003] The human heart is divided into four compartments or chambers. The left and right atria are located in the upper portion of the heart and the left and right ventricles are located in the lower portion of the heart. The left and right atria are separated from each other by a muscular wall, the intraatrial septum, while the ventricles are separated by the intraventricular septum.

[0004] Either congenitally or by acquisition, abnormal openings, holes, or shunts can occur between the chambers of the heart or the great vessels, causing blood to flow therethrough. Such deformities are usually congenital and originate during fetal life when the heart forms from a folded tube into a four chambered, two unit system. The deformities result from the incomplete formation of the septum, or muscular wall, between the chambers of the heart and can cause significant problems. Ultimately, the deformities add strain on the heart, which may result in heart failure if they are not corrected.

[0005] One such deformity or defect, a patent foramen ovale, is a persistent, one-way, usually flap-like opening in the wall between the right atrium and left atrium of the heart. Since left atrial pressure is normally higher than right atrial pressure, the flap typically stays closed. Under certain conditions, however, right atrial pressure exceeds left atrial pressure, creating the possibility for right to left shunting that can allow blood clots to enter the systemic circulation. This is particularly worrisome to patients who are prone to forming venous thrombus, such as those with deep vein thrombosis or clotting abnormalities.

[0006] Nonsurgical (i.e., percutaneous) closure of patent foramen ovales, as well as similar intracardiac defects such as atrial septal defects, ventricular septal defects, and left atrial appendages, is possible using a variety of mechanical closure devices. These devices, which allow patients to avoid the potential side effects often associated with standard anticoagulation therapies, typically consist of a metallic structural framework that is combined with a synthetic scaffold material. The synthetic scaffold material encourages ingrowth and encapsulation of the device. Current devices typically utilize a polyester fabric, expanded polytetrafluoroethylene (ePTFE), IvalonŽ, or a metal mesh as the synthetic scaffold material. Such devices suffer, however, from several disadvantages, including thrombus formation, chronic inflammation, and residual leaks.

SUMMARY OF THE INVENTION

[0007] The present invention provides a device for occluding intracardiac defects. The device includes a biological tissue scaffold, as opposed to a synthetic scaffold (e.g., a polyester fabric, ePTFE, IvalonŽ, or a metal mesh) as presently used by devices known in the art. In a preferred embodiment, the biological tissue scaffold is fabricated from collagen. In one embodiment, a specific type of biological tissue, derived from the tunica submucosa layer of the porcine small intestine, forms the tissue scaffold. As a result of this structure, the aforementioned disadvantages associated with the devices known in the art are minimized or eliminated.

[0008] In one aspect, the invention provides an intracardiac occluder for percutaneous transluminal treatment of an intracardiac defect. The intracardiac occluder includes a proximal support structure supporting a proximal occlusion shell and a distal support structure supporting a distal occlusion shell. The distal support structure is coupled to the proximal support structure and at least one of the occlusion shells includes a biological tissue scaffold.

[0009] Various embodiments of this aspect of the invention include the following features. The biological tissue scaffold may be a purified bioengineered type 1 collagen that may be derived from a tunica submucosa layer of a porcine small intestine. Further, in one embodiment, at least one of the support structures includes a corrosion resistant metal. Alternatively, at least one of the support structures includes a bioresorbable polymer or a biodegradable polymer. In yet another embodiment, the proximal support structure includes a plurality of outwardly extending proximal arms and the distal support structure includes a plurality of outwardly extending distal arms.

[0010] In another aspect, the invention provides a method for percutaneous transluminal treatment of an intracardiac defect in a patient. The method includes providing an intracardiac occluder as described above, positioning the intracardiac occluder proximate the intracardiac defect, and engaging the intracardiac defect with the intracardiac occluder to substantially occlude the intracardiac defect.

[0011] In one embodiment of this aspect of the invention, the intracardiac defect is engaged by positioning the proximal occlusion shell and the distal occlusion shell on different sides of the intracardiac defect. The intracardiac defect may be, for example, a patent foramen ovale, an atrial septal defect, a ventricular septal defect, or a left atrial appendage.

[0012] In yet another aspect, the invention provides a method for making an intracardiac occluder for the percutaneous transluminal treatment of an intracardiac defect. The method includes providing an overall support structure and first and second biological tissue scaffolds. The overall support structure includes a proximal support structure and a distal support structure. The method further includes coupling the first biological tissue scaffold to the proximal support structure and coupling the second biological tissue scaffold to the distal support structure. In various embodiments of this aspect of the invention, the biological tissue scaffolds are sewn, laminated, or glued to the support structures.

[0013] The foregoing and other objects, aspects, features, and advantages of the invention will become more apparent from the following description and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] In the drawings, like reference characters generally refer to the same parts throughout the different views. Also, the drawings are not necessarily to scale, emphasis instead generally being placed upon illustrating the principles of the invention.

[0015]FIG. 1 is a cutaway view of a heart illustrating an intracardiac defect.

[0016]FIG. 2A is a top plan view of an intracardiac occluder according to an illustrative embodiment of the invention.

[0017]FIG. 2B is a cross-sectional view of the illustrative intracardiac occluder of FIG. 2A.

[0018]FIG. 3A is a top plan view of an intracardiac occluder according to another illustrative embodiment of the invention.

[0019]FIG. 3B is a side view of the illustrative intracardiac occluder of FIG. 3A.

[0020]FIG. 4 is a perspective view of an intracardiac occluder according to another illustrative embodiment of the invention.

[0021] FIGS. 5A-5E illustrate the stages, according to an illustrative embodiment of the invention, for delivering an intracardiac occluder to an anatomical site in the body of a patient.

[0022]FIG. 6A illustrates the results from occluding an intracardiac defect with an intracardiac occcluder known in the art, 30-days after delivery of the intracardiac occluder.

[0023]FIG. 6B illustrates the results from occluding an intracardiac defect with an intracardiac occluder according to the invention, 30-days after delivery of the intracardiac occluder.

[0024]FIG. 7A illustrates the results from occluding an intracardiac defect with an intracardiac occcluder known in the art, 90-days after delivery of the intracardiac occluder.

[0025]FIG. 7B illustrates the results from occluding an intracardiac defect with an intracardiac occcluder according to the invention, 90-days after delivery of the intracardiac occluder.

DETAILED DESCRIPTION OF THE INVENTION

[0026] The present invention provides an intracardiac occluder for the repair of intracardiac defects, such as, for example, a patent foramen ovale, an atrial septal defect, a ventricular septal defect, and left atrial appendages. The intracardiac occluder includes a structural framework and a biological tissue scaffold adhered thereto.

[0027]FIG. 1 depicts a cutaway view of a heart 100. The heart 100 includes a septum 104 that divides a right atrium 108 from a left atrium 112. The septum 104 includes a septum primum 116, a septum secundum 120, and an exemplary intracardiac defect 124, which is to be corrected by the intracardiac occluder of the present invention, between the septum primum 116 and the septum secundum 120. Specifically, a patent foramen ovale 124 is shown as an opening through the septum 104. The patent foramen ovale 124 provides an undesirable fluid communication between the right atrium 108 and the left atrium 112. Under certain conditions, a large patent foramen ovale 124 in the septum 104 would allow for the shunting of blood from the right atrium 108 to the left atrium 112. If the patent foramen ovale 124 is not closed or obstructed in some manner, a patient is placed at high risk for an embolic stroke.

[0028]FIG. 2A depicts an intracardiac occluder 10 according to an illustrative embodiment of the invention. As shown, the intracardiac occluder 10 includes a proximal occlusion shell 18 (i.e., an occlusion shell that is closest to an operator of the intracardiac occluder 10 (e.g., a physician)), an opposite distal occlusion shell 20, and an overall support structure 16. The overall support structure 16 includes a proximal support structure 24, for supporting the proximal occlusion shell 18, and a distal support structure 34, for supporting the distal occlusion shell 20. In one embodiment, both the proximal support structure 24 and the distal support structure 34 include outwardly extending arms to support each of their respective occlusion shells 18, 20. As shown in FIG. 2A, for example, the proximal support structure 24 includes four outwardly extending arms 26 and the distal support structure 34 similarly includes four outwardly extending arms 36. In one embodiment, each outwardly extending arm is resiliently biased as a result of including three or more resilient coils 43 radially spaced from a center point 45. Alternatively, other resilient support structures could be used. In one embodiment, the eight arms 26, 36 are mechanically secured together by wire 52. Alternatively, other means, such as, for example, laser welding, may be used to secure the eight arms 26, 36 together. A cross-sectional view of the intracardiac occluder 10 illustrated in FIG. 2A, showing four arms 26, 36, is depicted in FIG. 2B.

[0029]FIGS. 3A and 3B depict an intracardiac occluder 10′ according to another illustrative embodiment of the invention. An overall support structure 16′ forms a clip and includes a proximal support structure 24′, for supporting a proximal occlusion shell 18′, and a distal support structure 34′, for supporting a distal occlusion shell 20′.

[0030] An intracardiac occluder 10″ according to yet another illustrative embodiment of the invention is illustrated in FIG. 4. Again, an overall support structure 16″ forms a clip and includes a proximal support structure 24″, for supporting a proximal occlusion shell 18″, and a distal support structure 34″, for supporting a distal occlusion shell 20″.

[0031] Alternatively, the overall support structure 16 may assume any shape or configuration to form the proximal support structure 24 and the distal support structure 34.

[0032] In one embodiment, the overall support structure 16 is fabricated from a corrosion resistant metal, such as, for example, stainless steel, nitinol, or a nickel-cobalt-chromium-molybdenum alloy (e.g., MP35N). Alternatively, in other embodiments, the overall support structure 16 is fabricated from bioresorbable or biodegradeable polymers.

[0033] In accordance with the present invention, the occlusion shells 18, 20, which are attached, as described below, to the proximal support structure 24 and the distal support structure 34, respectively, are made from a biological tissue scaffold. In a preferred embodiment, the tissue scaffold is fabricated from collagen. In one embodiment, a purified (acellular) bioengineered type 1 collagen derived from the tunica submucosa layer of the porcine small intestine forms the tissue scaffold. More specifically, the tunica submucosa layer, referred to hereinafter as the Intestinal Collagen Layer (“ICL”), is separated or delaminated from the other layers of the porcine small intestine (i.e., the tunica muscularis and the tunica mucosa) by any method known in the art. For example, a Bitterling sausage casing machine is used to perform the separation. Once mechanically separated from the other layers, the ICL is, in one embodiment, chemically cleaned to remove debris and other substances, other than collagen. For example, the ICL is soaked in a buffer solution at 4 degrees Celsius without the use of any detergents, or, alternatively, in a second embodiment, it is soaked with NaOH or trypsin. Other cleaning techniques known to those skilled in the art may also be used. After cleaning, the ICL is decontaminated. Any sterilization system for use with collagen, as known in the art, may be used. For example, a dilute peracetic acid solution, gamma sterilization, or electron-beam sterilization is used to decontaminate the ICL.

[0034] Alternatively, collagenous tissue from the fascia lata, pericardium, or dura matter of pigs or other mammalian sources, such as, for example, cows or sheep, may form the tissue scaffold. Additionally, in making the occlusion shells 18, 20, two or more collagen layers may be bonded together and then cross-linked to produce a biocompatible material capable of being remodeled by the host cells.

[0035] In one embodiment, the biological tissue scaffold is non-porous and prevents the passage of fluids that are intended to be retained by the implantation of the intracardiac occluder 10. In another embodiment, heparin is ionically or covalently bonded to the biological tissue scaffold to render it non-thrombogenic. In yet other embodiments, proteins or cells are applied to the biological tissue scaffold to render it non-thrombogenic and/or accelerate the healing process. Growth factors may also be applied to the biological tissue scaffold to accelerate the healing process.

[0036] Referring again to FIG. 2A, the occlusion shells 18, 20 are, in one embodiment, generally square in shape. Alternatively, the occlusion shells 18, 20 may assume other shapes. The biological tissue scaffold forming the occlusion shells 18, 20 is strong and flexible. The occlusion shells 18, 20 therefore easily attach to the overall support structure 16 and, as explained below, withstand sheath delivery to an anatomical site in the body of a patient. In one embodiment, the occlusion shells 18, 20 are sewn, as at 22A, 22B, with any commonly used suture material (e.g., a polyester suture) that threads through the distal ends 54 of the respective arms 26, 36 of the proximal support structure 24 and the distal support structure 34. Alternatively, the occlusion shells 18, 20 are laminated, glued, or attached by, for example, hooks or thermal welding to the proximal support structure 24 and the distal support structure 34. In yet another embodiment, the occlusion shells 18, 20 are laminated to the overall support structure 16 and, additionally, to one another, such that the overall support structure 16 is encapsulated entirely within the occlusion shells 18, 20.

[0037] FIGS. 5A-5E depict the stages for delivering the intracardiac occluder 10, according to an illustrative embodiment of the invention, percutaneously to an anatomical site in the body of a patient. Referring to FIG. 5A, a sheath 190 is first inserted into the intracardiac defect 186 as is typically performed by one skilled in the art. The intracardiac occluder 10 is then loaded into the lumen 188 of the sheath 190 and advanced throughout the lumen 188 until positioned at the distal end 192 of the sheath 190. Referring to FIG. 5B, the distal occlusion shell 20 of the intracardiac occluder 10 is released into the distal heart chamber 191 through the distal end 192 of the sheath 190. The distal occlusion shell 20 opens automatically and resiliently. The sheath 190 is then pulled back into the proximal heart chamber 193, as illustrated in FIG. 5C, to seat the distal occlusion shell 20 against the distal wall surface 194 of the intracardiac defect 186. The intracardiac defect 186 is thereby occluded from the distal side. As shown in FIG. 5D, the sheath 190 is then further withdrawn a sufficient distance to allow the proximal occlusion shell 18 to be released from the distal end 192 of the sheath 190. The proximal occlusion shell 18 opens automatically and resiliently to lie against the proximal surface 196 of the intracardiac defect 186, occluding the intracardiac defect 186 from the proximal side. The sheath 190 is then withdrawn from the patient's body, leaving behind the opened intracardiac occluder 10. As shown in FIG. 5E, the occlusion shells 18, 20 are positioned on either side of the intracardiac defect 186 and the intracardiac occluder 10 is permanently implanted within the body of the patient.

[0038] FIGS. 6A-6B and 7A-7B depict comparative 30-day and 90-day results, respectively, for the percutaneous closures of interventionally created intracardiac defects in sheep. Specifically, FIGS. 6A and 7A depict the 30-day and 90-day results, respectively, when an exemplary intracardiac occluder known in the art, whose occlusion shells were fabricated from a polyester fabric (i.e., a synthetic scaffold material), is used to occlude the intracardiac defect. FIGS. 6B and 7B depict the 30-day and 90-day results, respectively, when the intracardiac occluder 10 of the instant invention, whose occlusion shells 18, 20 were fabricated from ICL, is used to occlude the intracardiac defect.

[0039] As shown, the biological tissue scaffold of the intracardiac occluder 10 of the present invention increases the rate of tissue ingrowth and, consequently, decreases the time needed to completely close the intracardiac defect. Specifically, referring now to FIG. 7B, the intracardiac occluder 10 of the present invention is barely visible after 90-days. The surrounding tissue ingrowth nearly completely envelopes the intracardiac occluder 10. In comparison, referring now to FIG. 7A, the exemplary intracardiac occluder known in the art is still clearly visible after the same period of time.

[0040] As also shown, the intracardiac occluder 10 of the present invention naturally adheres to, and seals completely along, the edge of the intracardiac defect in a manner that is much improved from the exemplary intracardiac occluder known in the art. Additionally, in one embodiment, the biological tissue scaffold of the intracardiac occluder 10 of the present invention is non-porous. As a result, the intracardiac occluder 10 decreases the likelihood of fluid (e.g., blood) leakage through the opening.

[0041] Further advantages to the intracardiac occluder 10 of the present invention, in comparison to known intracardiac occluders, include decreased thrombogenicity, quicker endothelialization, superior biocompatibility, minimal foreign body reaction, decreased immunological and inflammatory responses, and no fibrosis.

[0042] Variations, modifications, and other implementations of what is described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention as claimed. Accordingly, the invention is to be defined not by the preceding illustrative description but instead by the spirit and scope of the following claims.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US621092 *Aug 25, 1897Mar 14, 1899 jocelyn
US3562820 *Aug 21, 1967Feb 16, 1971Bernhard BraunTubular sheet and strip form prostheses on a basis of biological tissue
US3874388 *Feb 12, 1973Apr 1, 1975Ochsner Med Found AltonShunt defect closure system
US3875648 *Apr 4, 1973Apr 8, 1975Dennison Mfg CoFastener attachment apparatus and method
US4006747 *Apr 23, 1975Feb 8, 1977Ethicon, Inc.Surgical method
US4007743 *Oct 20, 1975Feb 15, 1977American Hospital Supply CorporationOpening mechanism for umbrella-like intravascular shunt defect closure device
US4425908 *Oct 22, 1981Jan 17, 1984Beth Israel HospitalBlood clot filter
US4836204 *Jul 6, 1987Jun 6, 1989Landymore Roderick WMethod for effecting closure of a perforation in the septum of the heart
US4902508 *Jul 11, 1988Feb 20, 1990Purdue Research FoundationTissue graft composition
US4915107 *Feb 27, 1989Apr 10, 1990Harley International Medical Ltd.Automatic instrument for purse-string sutures for surgical use
US5021059 *May 7, 1990Jun 4, 1991Kensey Nash CorporationPlug device with pulley for sealing punctures in tissue and methods of use
US5108420 *Feb 1, 1991Apr 28, 1992Temple UniversityAperture occlusion device
US5192301 *Sep 3, 1991Mar 9, 1993Nippon Zeon Co., Ltd.Closing plug of a defect for medical use and a closing plug device utilizing it
US5222974 *Nov 8, 1991Jun 29, 1993Kensey Nash CorporationHemostatic puncture closure system and method of use
US5275826 *Nov 13, 1992Jan 4, 1994Purdue Research FoundationFluidized intestinal submucosa and its use as an injectable tissue graft
US5282827 *Mar 5, 1992Feb 1, 1994Kensey Nash CorporationHemostatic puncture closure system and method of use
US5284488 *Dec 23, 1992Feb 8, 1994Sideris Eleftherios BAdjustable devices for the occlusion of cardiac defects
US5304184 *Oct 19, 1992Apr 19, 1994Indiana University FoundationApparatus and method for positive closure of an internal tissue membrane opening
US5312341 *Aug 14, 1992May 17, 1994Wayne State UniversityRetaining apparatus and procedure for transseptal catheterization
US5312435 *May 17, 1993May 17, 1994Kensey Nash CorporationFail predictable, reinforced anchor for hemostatic puncture closure
US5411481 *Oct 27, 1992May 2, 1995American Cyanamid Co.Surgical purse string suturing instrument and method
US5413584 *May 7, 1993May 9, 1995Ethicon, Inc."Omega"-shaped staple for surgical, especially endoscopic, purposes
US5417699 *Dec 10, 1992May 23, 1995Perclose IncorporatedDevice and method for the percutaneous suturing of a vascular puncture site
US5425744 *Apr 18, 1994Jun 20, 1995C. R. Bard, Inc.Occluder for repair of cardiac and vascular defects
US5433727 *Aug 16, 1994Jul 18, 1995Sideris; Eleftherios B.Centering buttoned device for the occlusion of large defects for occluding
US5480424 *Nov 1, 1993Jan 2, 1996Cox; James L.Heart valve replacement using flexible tubes
US5486193 *May 1, 1995Jan 23, 1996C. R. Bard, Inc.System for the percutaneous transluminal front-end loading delivery of a prosthetic occluder
US5507811 *Nov 15, 1994Apr 16, 1996Nissho CorporationProsthetic device for atrial septal defect repair
US5540712 *Jun 1, 1994Jul 30, 1996Nitinol Medical Technologies, Inc.Stent and method and apparatus for forming and delivering the same
US5601571 *May 22, 1995Feb 11, 1997Moss; GeraldSurgical fastener implantation device
US5618311 *Sep 28, 1994Apr 8, 1997Gryskiewicz; Joseph M.Surgical subcuticular fastener system
US5620461 *Jan 5, 1995Apr 15, 1997Muijs Van De Moer; Wouter M.Sealing device
US5626599 *May 1, 1995May 6, 1997C. R. BardMethod for the percutaneous transluminal front-end loading delivery of a prosthetic occluder
US5634936 *Feb 6, 1995Jun 3, 1997Scimed Life Systems, Inc.Device for closing a septal defect
US5649950 *May 1, 1995Jul 22, 1997C. R. BardSystem for the percutaneous transluminal front-end loading delivery and retrieval of a prosthetic occluder
US5709707 *Nov 19, 1996Jan 20, 1998Children's Medical Center CorporationSelf-centering umbrella-type septal closure device
US5711969 *Apr 7, 1995Jan 27, 1998Purdue Research FoundationLarge area submucosal tissue graft constructs
US5720754 *Apr 28, 1995Feb 24, 1998Medtronic, Inc.Device or apparatus for manipulating matter
US5725552 *May 14, 1996Mar 10, 1998Aga Medical CorporationPercutaneous catheter directed intravascular occlusion devices
US5733294 *Feb 28, 1996Mar 31, 1998B. Braun Medical, Inc.Self expanding cardiovascular occlusion device, method of using and method of making the same
US5733337 *Apr 7, 1995Mar 31, 1998Organogenesis, Inc.Tissue repair fabric
US5741297 *Aug 28, 1996Apr 21, 1998Simon; MorrisDaisy occluder and method for septal defect repair
US5776162 *Jan 3, 1997Jul 7, 1998Nitinol Medical Technologies, Inc.Vessel implantable shape memory appliance with superelastic hinged joint
US5855614 *May 7, 1996Jan 5, 1999Heartport, Inc.Method and apparatus for thoracoscopic intracardiac procedures
US5861003 *Oct 23, 1996Jan 19, 1999The Cleveland Clinic FoundationApparatus and method for occluding a defect or aperture within body surface
US5879366 *Dec 20, 1996Mar 9, 1999W.L. Gore & Associates, Inc.Self-expanding defect closure device and method of making and using
US5885619 *Sep 16, 1997Mar 23, 1999Purdue Research FoundationLarge area submucosal tissue graft constructs and method for making the same
US5893856 *Jun 12, 1996Apr 13, 1999Mitek Surgical Products, Inc.Apparatus and method for binding a first layer of material to a second layer of material
US5902319 *Sep 25, 1997May 11, 1999Daley; Robert J.Bioabsorbable staples
US5904703 *Nov 7, 1997May 18, 1999Bard ConnaughtOccluder device formed from an open cell foam material
US6010517 *Apr 8, 1997Jan 4, 2000Baccaro; Jorge AlbertoDevice for occluding abnormal vessel communications
US6024756 *Dec 22, 1998Feb 15, 2000Scimed Life Systems, Inc.Method of reversibly closing a septal defect
US6056760 *Jan 30, 1998May 2, 2000Nissho CorporationDevice for intracardiac suture
US6077291 *Nov 26, 1996Jun 20, 2000Regents Of The University Of MinnesotaSeptal defect closure device
US6079414 *May 7, 1996Jun 27, 2000Heartport, Inc.Method for thoracoscopic intracardiac procedures including septal defect
US6080182 *Dec 19, 1997Jun 27, 2000Gore Enterprise Holdings, Inc.Self-expanding defect closure device and method of making and using
US6171329 *Aug 28, 1998Jan 9, 2001Gore Enterprise Holdings, Inc.Self-expanding defect closure device and method of making and using
US6174322 *Jul 31, 1998Jan 16, 2001Cardia, Inc.Occlusion device for the closure of a physical anomaly such as a vascular aperture or an aperture in a septum
US6187039 *Dec 10, 1997Feb 13, 2001Purdue Research FoundationTubular submucosal graft constructs
US6190353 *Oct 11, 1996Feb 20, 2001Transvascular, Inc.Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures
US6206895 *Oct 6, 1999Mar 27, 2001Scion Cardio-Vascular, Inc.Suture with toggle and delivery system
US6206907 *May 7, 1999Mar 27, 2001Cardia, Inc.Occlusion device with stranded wire support arms
US6206931 *Aug 22, 1997Mar 27, 2001Cook IncorporatedGraft prosthesis materials
US6214029 *Apr 26, 2000Apr 10, 2001Microvena CorporationSeptal defect occluder
US6217590 *Jul 15, 1999Apr 17, 2001Scion International, Inc.Surgical instrument for applying multiple staples and cutting blood vessels and organic structures and method therefor
US6228097 *Jan 22, 1999May 8, 2001Scion International, Inc.Surgical instrument for clipping and cutting blood vessels and organic structures
US6245080 *Sep 22, 2000Jun 12, 2001Scion Cardio-Vascular, Inc.Suture with toggle and delivery system
US6334872 *Jul 7, 1997Jan 1, 2002Organogenesis Inc.Method for treating diseased or damaged organs
US6342064 *Dec 22, 1999Jan 29, 2002Nipro CorporationClosure device for transcatheter operation and catheter assembly therefor
US6344049 *Sep 12, 2000Feb 5, 2002Scion Cardio-Vascular, Inc.Filter for embolic material mounted on expandable frame and associated deployment system
US6346074 *Jun 12, 1996Feb 12, 2002Heartport, Inc.Devices for less invasive intracardiac interventions
US6348041 *Mar 29, 2000Feb 19, 2002Cook IncorporatedGuidewire
US6352552 *May 2, 2000Mar 5, 2002Scion Cardio-Vascular, Inc.Stent
US6355052 *Feb 4, 1997Mar 12, 2002Pfm Produkte Fur Die Medizin AktiengesellschaftDevice for closure of body defect openings
US6364853 *Sep 11, 2000Apr 2, 2002Scion International, Inc.Irrigation and suction valve and method therefor
US6375625 *May 11, 2001Apr 23, 2002Scion Valley, Inc.In-line specimen trap and method therefor
US6375671 *Apr 17, 2000Apr 23, 2002Nipro CorporationClosure device for transcatheter operations
US6379342 *Apr 2, 1999Apr 30, 2002Scion International, Inc.Ampoule for dispensing medication and method of use
US6379368 *May 13, 1999Apr 30, 2002Cardia, Inc.Occlusion device with non-thrombogenic properties
US6387104 *Nov 12, 1999May 14, 2002Scimed Life Systems, Inc.Method and apparatus for endoscopic repair of the lower esophageal sphincter
US6398796 *Jan 10, 2001Jun 4, 2002Scion Cardio-Vascular, Inc.Suture with toggle and delivery system
US6402772 *Oct 17, 2001Jun 11, 2002Aga Medical CorporationAlignment member for delivering a non-symmetrical device with a predefined orientation
US6551344 *Jan 12, 2001Apr 22, 2003Ev3 Inc.Septal defect occluder
US6712836 *May 12, 2000Mar 30, 2004St. Jude Medical Atg, Inc.Apparatus and methods for closing septal defects and occluding blood flow
US6726696 *Jun 28, 2002Apr 27, 2004Advanced Catheter Engineering, Inc.Patches and collars for medical applications and methods of use
US20020010481 *Dec 20, 2000Jan 24, 2002Swaminathan JayaramanOcclusive coil manufacture and delivery
US20020019648 *Apr 18, 2001Feb 14, 2002Dan AkerfeldtIntra-arterial occluder
US20020026208 *Dec 7, 2000Feb 28, 2002Medical Technology Group, Inc.Apparatus and methods for delivering a closure device
US20020029048 *Aug 31, 2001Mar 7, 2002Arnold MillerEndovascular fastener and grafting apparatus and method
US20020032462 *Jun 10, 1999Mar 14, 2002Russell A. HouserThermal securing anastomosis systems
US20020043307 *Oct 23, 2001Apr 18, 2002Kiyoshito IshidaCore wire for a guide wire comprising a functionally graded alloy
US20020052572 *Sep 25, 2001May 2, 2002Kenneth FrancoResorbable anastomosis stents and plugs and their use in patients
US20020077555 *Jun 8, 2001Jun 20, 2002Yitzhack SchwartzMethod for anchoring a medical device between tissue
US20030028213 *Jul 30, 2002Feb 6, 2003Microvena CorporationTissue opening occluder
US20030045893 *Sep 6, 2001Mar 6, 2003Integrated Vascular Systems, Inc.Clip apparatus for closing septal defects and methods of use
US20030050665 *Sep 7, 2001Mar 13, 2003Integrated Vascular Systems, Inc.Needle apparatus for closing septal defects and methods for using such apparatus
US20030059640 *Aug 2, 2002Mar 27, 2003Denes MartonHigh strength vacuum deposited nitinol alloy films and method of making same
US20030065379 *Nov 4, 2002Apr 3, 2003Babbs Charles F.Reduction of stent thrombogenicity
US20030100920 *Sep 4, 2002May 29, 2003Akin Jodi J.Devices and methods for interconnecting conduits and closing openings in tissue
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7794474Mar 21, 2002Sep 14, 2010The Trustees Of Columbia University In The City Of New YorkEndovascular flexible stapling device
US7811297 *Dec 8, 2006Oct 12, 2010Teledyne Scientific & Imaging, LlcActuable structures and methods of fabrication and use
US8025495Aug 27, 2007Sep 27, 2011Cook Medical Technologies LlcApparatus and method for making a spider occlusion device
US8029532Oct 9, 2007Oct 4, 2011Cook Medical Technologies LlcClosure device with biomaterial patches
US8048110Jun 24, 2008Nov 1, 2011The Trustees Of Columbia University In The City Of New YorkEndovascular flexible stapling device
US8083768Dec 27, 2011Ensure Medical, Inc.Vascular plug having composite construction
US8167905Jun 17, 2008May 1, 2012The Trustees Of Columbia University In The City Of New YorkEndovascular flexible stapling device
US8308752Aug 27, 2007Nov 13, 2012Cook Medical Technologies LlcBarrel occlusion device
US8480707 *Jul 31, 2009Jul 9, 2013Cook Medical Technologies LlcClosure device and method for occluding a bodily passageway
US8734483 *Aug 27, 2007May 27, 2014Cook Medical Technologies LlcSpider PFO closure device
US8979941 *Aug 8, 2007Mar 17, 2015Coherex Medical, Inc.Devices for reducing the size of an internal tissue opening
US20040230185 *Feb 25, 2004Nov 18, 2004Cierra, Inc.Energy based devices and methods for treatment of patent foramen ovale
US20050021016 *Jun 21, 2004Jan 27, 2005Cierra, Inc.Energy based devices and methods for treatment of anatomic tissue defects
US20050034735 *Sep 18, 2003Feb 17, 2005Cierra, Inc.Methods and apparatus for treatment of patent foramen ovale
US20050131401 *Feb 2, 2005Jun 16, 2005Cierra, Inc.Energy based devices and methods for treatment of anatomic tissue defects
US20050131460 *Feb 7, 2005Jun 16, 2005Cierra, Inc.Methods and apparatus for treatment of patent foramen ovale
US20090317441 *Feb 7, 2007Dec 24, 2009Bilbo Patrick RBioengineered tissue constructs and cardiac uses thereof
US20100145382 *Feb 16, 2010Jun 10, 2010Nmt Medical, Inc.Tubular patent foramen ovale (pfo) closure device with catch system
US20130103061 *Apr 25, 2013John HarperDevice and method for treatment of incision or hernia
WO2008021969A2 *Aug 9, 2007Feb 21, 2008Coherex Medical IncMethods, systems and devices for reducing the size of an internal tissue opening
WO2008036478A2 *Aug 9, 2007Mar 27, 2008Coherex Medical IncDevices for reducing the size of an internal tissue opening
Classifications
U.S. Classification606/213
International ClassificationA61B17/12, A61B17/08, A61B17/00
Cooperative ClassificationA61B2017/00606, A61B2017/00575, A61B2017/00592, A61F2310/00365, A61B2017/1205, A61B17/12172, A61B17/12122, A61B17/0057
European ClassificationA61B17/12P5H, A61B17/12P7W1, A61B17/00P
Legal Events
DateCodeEventDescription
Oct 30, 2003ASAssignment
Owner name: NMT MEDICAL INC., MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEVELLIAN, CAROL A.;CARR, ROBERT M.;REEL/FRAME:014652/0319;SIGNING DATES FROM 20030930 TO 20031002
Jul 22, 2009ASAssignment
Owner name: SILICON VALLEY BANK,CALIFORNIA
Free format text: SECURITY AGREEMENT;ASSIGNOR:NMT MEDICAL, INC.;REEL/FRAME:022990/0295
Effective date: 20090626
Dec 16, 2010ASAssignment
Owner name: NMT MEDICAL, INC., MASSACHUSETTS
Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SILICON VALLEY BANK;REEL/FRAME:025641/0730
Effective date: 20101215
Jun 20, 2011ASAssignment
Owner name: W.L. GORE & ASSOCIATES, INC., ARIZONA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NMT MEDICAL, INC. (BY AND THROUGH JOSEPH F. FINN, JR., ASASSIGNEE FOR THE BENEFIT OF CREDITORS OF NMT MEDICAL, INC.);REEL/FRAME:026503/0273
Effective date: 20110616